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Induction of E-Cadherin in Lung Cancer and Interaction
with Growth Suppression by Histone Deacetylase Inhibition
Masatoshi Kakihana, MD,*† Tatsuo Ohira, MD,*† Daniel Chan, PhD,* Robin B. Webster, PhD,‡
Harubumi Kato, MD,† Harry A. Drabkin, MD,‡ and Robert M. Gemmill, PhD‡
Introduction: Loss of E-cadherin confers a poor prognosis in lung
cancer patients and is associated with in vitro resistance to endothelial
growth factor receptor inhibitors. Zinc finger E box-binding homeobox
(ZEB)-1, the predominant transcriptional suppressor of E-cad-
herin in lung tumor lines, recruits histone deacetylases (HDACs)
as co-repressors.
Methods: NSCLC cell lines were treated with HDAC inhibitors and
analyzed for E-cadherin induction, growth inhibition and apoptosis.
National Cancer Institute-H157 cells expressing ectopic E-cadherin
were tested for tumorigenicity in murine xenografts.
Results: We found that treatment with MS-275, compared to vori-
nostat (SAHA), valproic acid or trichostatin A, was most effective in
E-cadherin up-regulation and persistence in non-small cell lung
cancers. As with other tumor types and HDAC inhibitors, MS-275
inhibited growth and induced apoptosis. Importantly, blocking
E-cadherin induction by short hairpin RNA resulted in less inhibi-
tion by MS-275, implicating the epithelial to mesenchymal pheno-
type process as a contributing factor. In contrast to H460 and H661,
H157 cells were resistant to E-cadherin up-regulation by HDAC
inhibitors. However, E-cadherin was restored, in a synergistic man-
ner, by combined knockdown of ZEB-1 and ZEB-2. In addition,
H157 cells stably transfected with E-cadherin were markedly atten-
uated in their tumor forming ability. Lastly, combining MS-275 with
the microtubule stabilizing agent, paclitaxel, or 17-(allylamino)-17-
demethoxygeldanamycin, a heat shock protein 90 inhibitor, resulted
in synergistic growth inhibition. Since MS-275 has no reported
activity against HDAC6, which regulates both microtubule and heat
shock protein 90 functions, other mechanisms of synergy are antic-
ipated.
Conclusions: These results support the role of ZEB proteins and
HDAC inhibitors in the pathogenesis and treatment of lung cancer.
Key Words: Lung cancer, Histone deacetylase, Vorinostat, E-cad-
herin, ZEB, 17-AAG, Paclitaxel, NCI-H157, NCI-H661.
(J Thorac Oncol. 2009;4: 1455–1465)
Lung cancer is the leading cause of cancer deaths in theUnited States.1,2 Although early detection and prevention
have the potential to make a significant impact on lung cancer
mortality, current approaches, e.g., helical-computerized to-
mography, are still controversial.3–8 In addition, only modest
progress has been made in the treatment of locally progressed
or metastatic disease. One important advance has been
achieved with endothelial growth factor receptor (EGFR)
tyrosine kinase inhibitors, although responses are limited to a
small subset of tumors with EGFR mutations or copy number
increases.9,10 This responsive subset may also be further
restricted to tumors with amplifications of eIF3H and avian
myelocytomatosis viral oncogene homolog.11
Identification of biologic factors responsible for disease
pathogenesis or progression is a key strategy for development
of new interventional therapeutics. We and others have
shown that loss of E-cadherin in patients with non-small cell
lung cancer (NSCLC) is associated with a substantially in-
creased risk of early death.12,13 E-cadherin loss plays a pivotal
role in the transition of cells from an epithelial to mesenchy-
mal phenotype, which is associated with increased invasion
and metastases.14 In addition, we reported that E-cadherin
loss is associated with resistance to EGFR inhibitors15 and
that zinc finger E box binding homeobox (ZEB)-1 is the
predominant transcriptional suppressor of E-cadherin in
NSCLC cell lines.16 Of note, ZEB-1 also seems responsible
for inhibiting the tumor suppressor, SEMA3F.17 As ZEB
factors recruit histone deacetylase (HDAC) corepressors,
treatment with a class I/II HDAC inhibitor resulted in up-
regulation of both E-cadherin16 and SEMA3F.17 Moreover,
HDAC inhibitors decreased binding of ZEB-1 to the SEMA3F
promoter, at least in National Cancer Institute (NCI)-H661 cells.
HDAC inhibitors block cancer cell growth by multiple
mechanisms including sensitizing cells to apoptosis, cell-
cycle inhibition, downregulation of angiogenic factors, and,
as recently described, proteasome inhibition.18–21 HDAC in-
hibitors have been combined with multiple agents in human
cancer cells with promising preliminary results. These agents
include methylation and multityrosine kinase inhibitors,22,23
peroxisome proliferator-activated receptor  agonists,24 tu-
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mor necrosis factor-related apoptosis-inducing ligand,25 and
single-agent (e.g., etoposide)26 and combination chemother-
apy (e.g., carboplatin plus paclitaxel).27,28
Heat shock protein (HSP) 90 is a chaperone that regu-
lates the folding and stability of many proteins involved in
cancer (e.g., avian erthroblastic leukemia viral oncogene
homolog-B2, v-raf-1 murine leukemia viral oncogene ho-
molog, and hypoxia inducible factor-1). In hematologic
neoplasms, HDAC and HSP90 inhibitors have been success-
fully combined.29,30 However, there is little published infor-
mation regarding this combination in lung cancer cells. Of
note, the function of HSP90 is regulated by acetylation. Both
mutations and HDAC inhibitors that affect HSP90 acetylation
have been reported to inhibit the binding of client proteins
and other chaperones.31 Although HDAC6 has a particular
role in deacetylating HSP90, other HDACs also seem to be
involved.
In this study, we observed that E-cadherin was induced
in NSCLC cell lines by multiple HDAC inhibitors, with the
class I inhibitor, MS-275, yielding the strongest response and
persistence of expression after agent removal. HDAC inhibi-
tion also reduced growth rates and induced apoptosis, as
evidenced by flow cytometry and poly ADP ribose polymer-
ase (PARP) cleavage. Although HDAC inhibitors have been
reported to affect the expression of many hundreds of
genes,32 we found that blocking the upregulation of E-cad-
herin by short interfering RNA (siRNA) made cells signifi-
cantly more resistant to MS-275. This suggests that the
observed negative effects on growth/proliferation by HDAC
inhibitors stems, in part, from the epithelial to mesenchymal
phenotype and especially E-cadherin. The role of ZEB-1/2 in
these processes was supported by the finding that combined
ZEB1/2 knockdown was necessary to restore E-cadherin in
NCI-H157 cells, which are refractory to HDAC inhibitors.
Moreover, E-cadherin transfectants of H157 were signifi-
cantly impaired in their ability to form tumors in nude mice.
Combinations of MS-275 with taxotere, or the HSP90 inhib-
itor, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG)
resulted in synergistic growth inhibition in most NSCLC cell
lines examined.
METHODS
Cell Lines
Fourteen cell lines derived from NSCLC lung cancers
(NCI-H157, -H290, -H292, -H322, -H460, -H513, -H647,
-H661, -H1648, -H1703, -H1793, -H1299, -H2122, and
A549) and two additional lines, NCI-H28 (mesothelioma)
and NCI-1334 (origin unclear) were used. Cells were routinely
cultured in RPMI 1640 (InVitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum, 2.5% glutamine, 50,000
units penicillin, and 80-M streptomycin in a humidified 5%
CO2 atmosphere. E-cadherin-expressing variants of NCI-H157
were generated by CaPO4-mediated cotransfection with
pEGFP-C1 and the -actin promoter-based expression vector
pBATEM containing human wild-type E-cadherin.33 G418
resistant colonies were expanded and subcloned by single cell
sorting using the flow cytometry core facility of the Univer-
sity of Colorado Cancer Center.
Reagents
MS-275 (batch number: 81300002; high perfor-
mance liquid chemotherapy purity, 99.82%) was supplied as
a crystalline white powder by Schering AG (Berlin, Germany),
and vorinostat (VOR, suberoylanilide hydroxamic acid) was
obtained from Aton Pharma (Lot no. AP-390-1, Tarrytown,
NY). Both HDAC inhibitors were dissolved in dimethyl
sulfoxide at 10 mM, and final dimethyl sulfoxide concentra-
tions in medium did not exceed 0.01%. Valproic acid (VPA),
trichostatin A (TSA), and 17-AAG were purchased from
Sigma (St. Louis, MO). HDAC inhibitors were used at
micromolar concentrations, generally in the range of 1 to 10
M. Treatment times were as indicated in the figure legends.
Gene Knockdown
Oligonucleotides targeting E-cadherin (CDH1), designed
for expression from pSuperior.puro (OligoEngine, Inc.), were
prepared from messenger RNA (mRNA) position 299 to 317
(NM_004360). Oligos were (forward) 5-GATCCGATTGCA-
CCGGTCGACAAATTCAAGAGATTTGTCGACCGGTGCA-
ATCTTTTTTGGAAC and (reverse) 5-TCGAGTTCCAAA-
AAAGATTGCACCGGTCGACAAATCTCTTGAATTTGTC-
GACCGGTGCAATCG. Mutant control oligos were (forward)
5-GATCCGATTGCACAGGTCGACAAATTCAAGAGATT-
TGTCGACCTGTGCAATCTTTTTTGGAAC and (reverse)
5-TCGAGTTCCAAAAAAGATTGCACAGGTCGACAAA-
TCTCTTGAATTTGTCGACCTGTGCAATCG. Oligos were
annealed and ligated to BglII/XhoI cleaved vector. Clones
were sequence verified. NCI-H661 cells were electroporated
with 1 g of each short hairpin RNA (shRNA) construct and
colonies selected with 3 g/ml puromycin. Effective knock-
down of E-cadherin was verified by Western blot after in-
duction by MS-275 (Figure 3B). For ZEB-1 and -2, prevali-
dated siRNAs were acquired from Invitrogen, and one with
the highest knockdown efficiency and specificity for each
target gene was chosen for further analysis (cat no.
HSS110549 for ZEB-1; no. HSS190654 for ZEB-2). No
significant advantage was observed with the use of more than
one siRNA against the same target. Transfections were per-
formed using HiPerFect according to manufacturer’s recom-
mendations (Qiagen, Inc.). Cells were plated at 40 to 60%
confluency and transfected 15 hours later with final concen-
trations of 5nM. Media were replaced at 24 hours and
harvested for analysis at 96 hours posttransfection.
Total RNA was isolated using the RNAeasy kit (Qia-
gen, Inc.) and quantitated spectrophotometrically. Equimolar
amounts were reverse-transcribed using SuperScript III First-
Strand Synthesis SuperMix (Invitrogen) according to manu-
facturer’s instructions. Real-time detection of target cDNA was
performed using 2L of 1:5 diluted cDNA in 20L total reaction
volumes in 96-well plates. Amplifications were analyzed on an
ABI 7500 real-time PCR machine, using AmpliTaq Gold with
UNG Amperase (Applied Biosystems) according to manufac-
turer’s instructions. Primer sequences were ZEB-1_Forward,
5-AGCAGTGAAAGAGAAGGGAATGC-3, ZEB-1_Reverse
5-GGTCCTCTTCAGGTGCCTCAG-3 Reverse; ZEB-2_For-
ward, 5-AACCCAAGGAGCAGGTAATCG-3, and ZEB-
2_Reverse, 5-GGAACCAGAATGGGAGAAACG-3. Nor-
malization primers have been described.34
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Orthotopic Nude Rat Tumorigenicity Assay
We previously documented that lung cancer cell lines
grown orthotopically in nude rats had similar metastatic
characteristics to that of humans with lung cancer.35,36 The
effects of E-cadherin on tumorigenicity and metastatic be-
havior of NCI-H157 cells were evaluated using this model.
Six to eight-week-old female athymic nude rats were ob-
tained from the National Cancer Institute and maintained in
pathogen-limited conditions at the Animal Resources Center,
University of Colorado Health Sciences Center. One day
before tumor implantation, rats were treated with 450 cGy of
total body irradiation (Co60) to increase immunosuppression
and the subsequent rate of tumor establishment. Green fluo-
rescence protein (GFP)-tagged human H157 subclones (1 
107 cells in 100 L saline) were carefully instilled into the
left lung by intratracheal administration through a special
3-inch 22-gauge catheter (Popper & Sons, Inc., New Hyde
Park, NY). Briefly, each rat was anesthetized by isofurane
inhalation and held upright at 60° on a slant platform with a
rubber band through its incisor teeth. The mouth cavity was
opened by holding the animal’s tongue and illuminated with
a bright Cool-Light Source (Dolan-Jenner Industries, Law-
rence, MA). Single cell suspensions were loaded into a
syringe fitted with a blunt-ended Popper disposable catheter.
The blunt end was also bulged, so that it would not catch on
and tear delicate tissues during insertion into the lungs. The
catheter was inserted, bypassing the trachea and left bronchus
of each animal, and cells delivered into the left lobe of the
lung. The procedure was performed aseptically and required
2 to 3 minutes/rat. Animals recovered within 5 minutes
without casualty or showing signs of stress, were monitored
for an additional 5 minutes, and then returned to cages.
Animals were monitored daily for clinical signs and body
weights measured weekly. Survival was measured from the
first day of tumor implantation until the end of the study (day
60 or 120). Digital pictures were taken of all lungs isolated
from animals, which died due to tumor burden or at the time
of euthanasia, using an Olympus 2500L Digital Camera.
Animal care and use were conducted in accordance with all
applicable regulations and was approved by the University of
Colorado Institutional Animal Care and Use Committee.
Western Blot Analysis
After treatment, cell cultures were chilled on ice,
washed twice with ice-cold phosphate-buffered saline (PBS)
and frozen at 80°C. Cells were disrupted in lysis buffer (20
mM TrisHCl, pH 8.0/100 mM NaCl/0.5% Igepal/0.5 mM
phenylmethylsulfonylfluride/10 g/ml leupeptin/5 g/ml
pepstatin A/2.1 g/ml aprotinin) on ice and then sonified for
15 seconds. Insoluble material was removed by centrifuga-
tion (10,000g, 3 minutes) and protein concentrations deter-
mined by Bradford assays. Samples were mixed with Lae-
mmli sample buffer and 10 g aliquots resolved on sodium
dodecyl sulfate/polyacrylamide gel electrophoresis gels. Af-
ter transfer to PVDF membranes (Millipore), immunodetec-
tion was performed according to the manufacturer’s instruc-
tions. Antibodies were obtained from the following sources:
E-cadherin (C20820) and active-caspase 3 (No. 551150) from
BD Biosciences/Transduction Laboratories, (San Jose, CA),
tubulin (Ab-4, NeoMarkers/LabVision, Fremont, CA), histone
H4 and acetylated histone H4 (Upstate Cell Signaling Solutions,
Lake Placid, NY), PARP (cat no. 1835238, Roche Applied
Sciences, Indianapolis, IN), Bcl-2, and ZEB-1 (Santa Cruz
Biotechnology, Santa Cruz, CA). All antibodies were used at
manufacturer’s recommended dilutions in PBS/1% Tween
containing 1.0% nonfat dry milk. Detection used horseradish
peroxidase-conjugated secondary antibodies and chemilumi-
nescence (Western Lightning, Perkin-Elmer) or infrared flu-
orescence using an Odyssey scanner (LiCor, Lincoln, NE).
Chemiluminescence signals were quantified by densitometry
using a Chemi-Imager from Alpha Inotech (San Leandro,
CA). Total cellular histones were purified using an acid
extraction protocol provided by the antihistone antibody sup-
plier (Upstate, Lake Placid, NY).
MTT Cell Growth Assay and Combination
Index
Growth inhibition of lung cancer cell lines was deter-
mined by the use of the colorimetric dimethylthiazol tetrazo-
lium bromide (MTT) cell viability assay as described previ-
ously.37 Briefly, cells were seeded in 96-well microtitre plates
at 3000 cells/well (except 4000 cells/well for H290 and
H2122 and 5000 cells/well for H322) and allowed to adhere
overnight. Agents were added to appropriate concentrations
and incubation continued for an additional 72 to 96 hours.
MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tet-
razolium bromide, Sigma) was then added to 400 g/ml and
incorporated for 2 to 4 hours. Deposited dye was solubilized
with 75% isopropanol and 240 mM HCl, and absorbance was
measured at 490 nm in a 96-well plate reader (Molecular
Devices, Inc.). The combination index (CI) was calculated by
CALCUSYN.38 CI values 1.0 suggested synergy, and val-
ues  1.0 indicated additivity, whereas values 1.0 sug-
gested antagonism.
Apoptosis Quantitation by YO-PRO-1 Staining
Apoptosis was assessed by in situ staining using the
Vybrant apoptosis assay kit no. 4 (Molecular Probes, Eugene,
OR). This method relies on the DNA-binding and membrane-
impermeable green fluorescent dye, YO-PRO-1.39 After treat-
ments, cells were washed, resuspended in 1.0 mL of PBS, and
1 L/ml YO-PRO-1, and propidium iodide were added. Cells
were incubated for 30 minutes on ice and then analyzed by
flow cytometry (FACScan; Becton Dickinson, Franklin
Lakes, NJ) through the University of Colorado Flow Cytom-
etry Core facility. Fluorescence emissions were monitored at
530 nm (YO-PRO-1  apoptotic) and 575 nm (propidium
iodide  necrotic). The Apoptotic Index was calculated as
the number of apoptotic cells/total cells (10,000 minimum).
Data were analyzed using CellQuest software (Becton Dick-
inson). All observations were reproduced at least three times
in independent experiments.
Statistical Methods
IC50 values and standard deviations were estimated
using linear interpolation between the doses about the 50%
inhibition point. CI values were obtained using the methods
of Chou and Talalay.38 Survival curves were obtained using
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the method of Kaplan and Meier.40 A two-way analysis of
variance with interaction was used to compare growth inhibition
between control and knockdown cells across doses of MS-275.
Post hoc comparisons using Tukey’s honestly significant differ-
ence (HSD) were applied at each dose to compare growth across
groups. All hypothesis tests were performed at the 0.05 level of
significance.
RESULTS
E-Cadherin is Induced by Multiple HDAC
Inhibitors
We previously reported that the HDAC inhibitor TSA
induced E-cadherin in the NSCLC cell lines, NCI-H661 and
NCI-H460.16 To extend these results, we compared several
HDAC inhibitors for their ability to upregulate E-cadherin
over time. Cells were treated with indicated doses of TSA,
VPA, benzamide (MS-275) or VOR (suberoylanilide hydrox-
amic acid), and protein lysates analyzed by Western blot. As
can be seen in Figure 1A, E-cadherin induction and persis-
tence differed in a cell line and agent-dependent fashion, with
the highest levels consistently observed at 24 hours. A dose-
response analysis demonstrated that H661 cells were highly
responsive to both MS-275 and VOR (Figure 1B), even at 1
M. When H661 cells were pretreated with MS-275 for 12
hours, then drug was washed away, E-cadherin persisted for
4 days, whereas TSA effects were lost after 24 hours (Figure
1C). Acetylated histone H4 accumulation verified efficacy of
HDAC inhibitors (Figure 1D).
Growth Inhibition by HDAC Inhibitors is
Dependent, in Part, on E-Cadherin Induction
HDAC inhibitors have been reported to block growth of
lung cancer cell lines.41 Growth inhibition by MS-275 was
verified in 12 NSCLC cell lines using MTT assays. Inhibition
curves are shown for three representative lines in Figure 2,
whereas corresponding IC50 values for all lines are listed in
Table 1. Similar to reports using VOR treatment, we observed
IC50 values for MS-275 ranging from less than 0.3 M
(H2122) to approximately 10 M (H322).
We previously reported that loss of E-cadherin (or
-catenin) was a poor prognostic factor in lung cancer.12
Moreover, transfected E-cadherin suppressed in vitro growth
and sensitized NCI-H157 cells to the EGFR inhibitor, ge-
fitinib.15 To determine whether E-cadherin induction con-
tributed to the antiproliferative effects of HDAC inhibi-
tion, we stably knocked down E-cadherin (CDH1) mRNA
in H661 cells with a shRNA construct, using a nontarget-
ing shRNA as control. E-cadherin was induced by MS-275
(at 1, 2.5, and 5 M) in control cells after 24 hours (Figure
FIGURE 1. Induction of E-cadherin in non-small cell lung cancer (NSCLC) cell lines by histone deacetylase (HDAC) inhibition.
A, Time course of E-cadherin induction in H661 and H460 cells with trichostatin A (TSA), valproic acid (VPA), MS-275, and
vorinostat (VOR). The indicated concentrations of each agent were added to cultures at time zero and samples taken over 4
days; agents were present throughout the time course. Equal aliquots of protein lysates were immunoblotted for E-cadherin.
Equivalent loading was verified using anti--actin (H661) or Coomassie blue staining (H460, Coom.). B, Dose-response to MS-
275 and vorinostat. Cultures of H661 and H460 cells were treated with the indicated concentrations of MS-275 or vorinostat
for 24 hours and analyzed for E-cadherin levels and actin. C, Persistence of E-cadherin induction. H661 cells were treated with
TSA or MS-275 for 12 hours followed by wash out with fresh medium at zero time. Samples were then harvested at the indi-
cated time points and analyzed for E-cadherin and actin. D, Time course of acetylated histone H4 accumulation by HDAC in-
hibitors. H661 and H460 cells were treated with the indicated concentrations of TSA and VPA and samples analyzed for acety-
lated Histone H4 levels over time.
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3A, left panel), whereas induction was substantially blunted in
CDH1 knockdown cells (right panel). Differential effects
on growth inhibition were then assessed by MTT assays
(Figure 3B). Specific reduction of E-cadherin increased the
resistance to growth inhibition by MS-275 at both 2 and 4
M, and the latter was statistically significant (p  0.001,
Tukey’s HSD test). These results suggest that induction of
E-cadherin contributes to the growth inhibition of NSCLC
cells mediated by MS-275 and probably other HDAC
inhibitors.
ZEB-1/2-Dependent but HDAC Class I/II
Independent Suppression of E-Cadherin
Our previous work showed that ZEB-1 was the pre-
dominant transcriptional repressor of E-cadherin in NSCLC
cell lines.15,16 ZEB recruits the corepressor CtBP,14 which
complexes with several HDACs including HDAC1/2 (class I)
and HDACs 4 and 7 (class II).42 During testing for HDAC
inhibitor effects, we discovered that H157 cells were resistant
to E-cadherin upregulation at both the protein (Figure 4A) and
mRNA levels (not shown). To determine whether ZEB was
responsible for E-cadherin repression in this line, we knocked
down ZEB-1 and ZEB-2 (SIP1/Zfhx1B), separately or together,
and analyzed CDH1 mRNA and E-cadherin protein. As shown
in Figure 4B, individual knockdowns of ZEB-1 or ZEB-2 led to
modest increases in E-cadherin mRNA, but this was insufficient
to detect E-cadherin protein (Figure 4C). However, the com-
bined knockdown of ZEB-1 and ZEB-2 led to a 1000-fold
increase in E-cadherin mRNA and robust expression of
E-cadherin protein (lane 6). Thus, E-cadherin suppression in
H157 cells is ZEB dependent but independent of class I/II
HDAC enzymes (see Discussion section). Several additional
lines expressing low to no E-cadherin15 were treated with TSA
and MS-275 to determine whether resistance to HDAC inhibi-
tors was unique to H157 cells. MS-275 increased mature
FIGURE 2. Growth inhibition after MS-275 treatment in
non-small cell lung cancer (NSCLC) lines. Dimethylthiazol
tetrazolium bromide (MTT) growth assays for three repre-
sentative cell lines show the extreme responses among the
panel of 12 NSCLCs tested. Cells were seeded into 96-well
microtitre plates at between 2000 and 5000/well. MS-275
was added from 25 nM to 25 M and treatment continued
for 3 days. IC50 values for the complete cell line panel are
provided in Table 1.
FIGURE 3. E-cadherin induction contributes to antiprolif-
erative effects of histone deacetylase (HDAC) inhibition. A,
National Cancer Institute-H661 cells were stably transfected
with a shRNA construct targeting cadherin (CDH) 1 mRNA
or a nontargeting control. Transfected cells were tested for
E-cadherin protein levels by Western blot after 24 hours MS-
275 treatment using the indicated doses. B, E-cadherin
knockdown increased resistance to MS-275. Dimethylthiazol
tetrazolium bromide (MTT) assays were performed on con-
trol and CDH1 knockdown H661 cells. Values are the aver-
age of two independent experiments, each performed in
triplicate. Growth was significantly restored in CDH1 knock-
down cells compared with controls when treated with 4 M
MS-275 (p  0.001, Tukey’s honestly significant difference
test).
TABLE 1. IC50 for MS-275
Cell
Line
IC50 (M)
a
MS-275
Relative
Bcl-2 Exp
% Apoptoticb
MS-275
Resistant H322 9.18  1.64 12 15  1
H1793 5.48  1.19 2 ND
A549 3.42  0.92 1 5  0
Moderate H513 2.00  0.6 0.2 36  3
H647 1.74  0.31 12 59  17
H292 1.15  0.24 2 32  3
Sensitive H290 0.79  0.13 18 36  17
H157 0.75  0.21 14 36  13
H460 0.55  0.10 19 28  7
H1648 0.45  0.15 5 ND
H661 0.43  0.12 0 40  3
H2122 0.26  0.06 2 53  10
a Values are means  SD for three experiments, each done in triplicate.
b Values for H322 and H2122 were done in duplicate.
ND, not determined.
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E-cadherin (120 kDa) in H2122 cells, but two other lines were re-
sistant (Figure 4A). Thus, HDACi treatments may restore
E-cadherin in approximately one-half of negative tumors.
E-Cadherin Blocks Tumorigenicity of
NCI-H157 Cells
H157 cells form aggressive tumors in an orthotopic
nude rat model. To test the effects of E-cadherin expression
on tumorigenicity, H157 cells were stably cotransfected with
an E-cadherin expression vector together with a GFP vector
carrying G418 resistance (Figure 5A). Two independent
transfectants (E1 and E6) were examined. Tumors developed
rapidly from H157/GFP control cells and metastasized to the
right lung and mediastinal lymph nodes (Figure 5B, left, black
arrowhead). However, tumor formation was suppressed by re-
expression of E-cadherin. After nearly 4 months, H157/E6 cells
yielded only small primary tumors (white arrowhead). Kaplan-
Meier survival statistics confirmed the aggressive nature of
H157/GFP control tumors while most animals survived beyond
60 days when E-cadherin was reexpressed (Figure 5C).
Combining the HDAC Inhibitor, MS-275, with
17-AAG or Taxotere Results in Synergistic
Growth Inhibition
We then examined the addition of a proteasome inhib-
itor, PS341 (Bortezomid), HSP90 inhibitor, 17-AAG [17-
(allylamino)-17-demethoxygeldanamycin],43 or a microtu-
bule-targeting agent, taxotere, to determine whether these would
enhance the antiproliferative effects of MS-275. The combina-
tion with PS341 proved inconsistent and was not further studied.
However, the addition of either 17-AAG or taxotere resulted in
consistent synergistic growth inhibition in most lines.
As a single agent, 17-AAG inhibited growth with IC50
values ranging between 20 and 300 nm. With MS-275, the CI
values ranged between 0.3 and 0.8 (Table 2), indicative of
synergy. In H322 cells, which were relatively resistant to MS-
FIGURE 4. Zinc finger E box-binding homeobox (ZEB)-1 and -2 inhibit E-cadherin in H157 cells in a histone deacetylase
(HDAC) class I/II independent manner. A, Six non-small cell lung cancer (NSCLC) cell lines with negative or low-E-cadherin
expression were treated for 24 hours with trichostatin A (TSA, 0.33 M) or MS-275 (5 M). Protein lysates (10 g) were ana-
lyzed for induced E-cadherin levels on Western blots. E-cadherin remained undetectable in H157, H1299, and H1703 cells af-
ter HDACi treatment. E-cadherin precursor (135 kDa) was observed only in H2122 (mature E-cadherin migrates at 120 kDa).
B, Synergistic induction of E-cadherin message by joint knockdown of ZEB-1 and -2. H157 cells were mock transfected (mock)
or transfected with control, ZEB-1, or ZEB-2-specific siRNAs, alone and in combination. Cells were harvested 48 hours post-
transfection and processed for RNA and protein. ZEB-1, ZEB-2 and CDH1 were analyzed by real-time reverse-transcriptase
polymerase chain reaction (RT-PCR); bars are plotted as log10 of expression relative to glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). C, Protein samples from similarly treated cells were analyzed for ZEB-1 and E-cadherin on Western blots.
ZEB-1-specific siRNA achieved substantial knockdown of protein (B, lane 3), but no further knockdown was observed on addi-
tion of a second anti-ZEB-1 siRNA (B and C, lane 4). Knockdown of ZEB-2 was verified by real-time PCR because available anti-
ZEB-2 antibodies were nonspecific. E-cadherin was detectably induced only in cells knocked down for both ZEB-1 and -2 (lane
6).
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275, the addition of 17-AAG increased the sensitivity to the
HDAC inhibitor by approximately 10-fold. However, this was
cell line dependent, because the combination was antagonistic in
H1793 cells, and only a modest change in sensitivity was
observed in A549. Similar results were obtained with taxotere.
As a single agent, taxotere inhibited growth in all cell lines with
IC50 values ranging from 2 to 65 nM. The combination resulted
in synergistic growth inhibition, with CI values ranging from
0.08 to 0.55 (Table 3). Peak synergistic interactions with MS-
275 were frequently observed at taxotere levels of one half to
one third of individual IC50 values. Notably, the three most
resistant lines to MS-275 demonstrated a 10 to 20-fold increased
sensitivity on addition of taxotere.
Treatment with HDAC inhibitors led to morphologic
changes consistent with apoptosis and detachment from sub-
strate. YO-PRO1 staining and flow cytometry were used to
quantify apoptotic effects in 10 lines after treatment with
either TSA (0.33 M) or MS-275 (10 M). TSA induced
early apoptosis (YO-PRO1-positive) in about 60% of H661
cells after 48 hours (Figure 6B). Similarly, 36% of H290 cells
underwent apoptosis with MS-275 (Figure 6D). The percent
of apoptotic cells treated with MS-275 at their IC50 for 24
hours is shown in Table 1. Additional evidence of apoptosis
was obtained using activated caspase-3 and cleaved PARP, as
shown for NCI-H647 cells (Figure 6E), which were moder-
ately sensitive to MS-275 in terms of growth inhibition. In
contrast, resistant A549 cells showed little caspase activation
and lower levels of cleaved PARP. Similar results were
obtained using either variable doses for 36 hours or a single
dose (5 M) during a 2-day time course (Figure 6F).
There was no apparent correlation between the ob-
served growth inhibition (using MTT assays at 72–96 hours)
FIGURE 5. E-cadherin expression blocks tumorigenicity of NCI-H157 cells. A, NCI-H157 cells were stably cotransfected with
pEGFP-C1 and an E-cadherin expression construct (independent clones in lanes 3 and 4, pBATEM) or pEGFP-C1 alone (lane 2).
Western blot for E-cadherin verified expression (top), whereas tubulin provided a loading control (bottom). B, Orthotopic tumorige-
nicity assay. Ten million cells (H157/GFP controls or H157/E-cadherin transfectants) were introduced intratracheally into the left
lung of irradiated athymic nude rats (six/group) and tumor growth monitored for 60 days. H157 cells stably transfected with EGFP-C1
formed rapidly growing, metastatic tumors by 42 days postinoculation (dark arrowhead). The E6 transfectant at 123 days had formed a
typically small tumor (white arrowhead) in the left lung without metastasis. C, Kaplan-Meier survival plots are shown for animals
injected with the indicated transfectants (six animals/group). GFP, green fluorescence protein; NCI, National Cancer Institute.
TABLE 2. 17-AAG IC50 and Combination Index with MS-275
Cell Line Histology
IC50 (M)
a
17-AAG
IC50 (M)
a
MS-275 CI
	MS-275/17-AAG

at Peak Synergy
H647 Ad-sq 0.449  0.27 1.74  0.31 0.51 0.5/0.05b
H322c Bac 0.393  0.098 9.18  1.64 0.33 1.0/0.05
H290 Meso 0.323  0.148 0.79  0.13 0.45 0.75/0.5
H661 Large 0.157  0.474 0.43  0.12 0.53 0.25/0.5
H1793 Adeno 0.083  0.02 5.48  1.19 31.80 Antagonistic
H513 Meso 0.073  0.024 2.00  0.6 0.82 0.05/0.005
H292 Mucoepi 0.067  0.005 1.15  0.24 0.42 0.1/0.1
H157 Squamous 0.051  0.013 0.75  0.21 0.35 0.1/0.02
H1648 Adeno 0.021  0.009 0.45  0.15 0.36 0.25/0.005
A549 Adeno 0.021  0.003 3.42  0.92 0.64 2.5/0.001
H460 Large 0.019  0.003 0.55  0.1 6.87 Antagonistic
H2122d Adeno 0.011  0.001 0.26  0.06 0.31 0.01/0.05
a Values are means  SD for three experiments, each done in triplicate.
b All concentrations listed as M.
c Seeded with 5000 cells/well.
d Seeded with 4000 cells/well.
17-AAG, 17-(allylamino)-17-demethoxygeldanamycin; CI, combination index.
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and apoptosis (performed after 24 hours of treatment), i.e.,
Spearman r  0.244, p  0.56. This suggests that the
mechanism of growth inhibition by HDAC inhibitors in-
cludes factors in addition to apoptosis. In support of this, we
also examined Bcl-2 levels by Western blot (Figure 6G) and
compared the densitometry measurements with growth inhi-
bition by MS-275. No significant correlation was detected,
i.e., Spearman r  0.049; p  0.879, and some resistant
lines (e.g., A549 and H1793) expressed lower Bcl-2 levels
than sensitive ones (e.g., H647). Thus, together with the
YO-PRO1 staining, we conclude that these assessments of
apoptosis and Bcl-2 levels do not significantly correlate with
growth inhibition by MS-275 (as a single agent).
DISCUSSION
E-cadherin loss is associated with enhanced invasion
and metastases in many epithelial-derived tumors.12,44–48 In
lung cancer, we previously reported that reduced E-cadherin
was associated with loss of differentiation, increased inva-
sion, and metastasis and reduced survival.12 Among other
transcriptional repressors in lung cancer cell lines, we found
that ZEB-1 levels best correlated with reduced E-cadherin
expression and that blocking ZEB-1 with either siRNA or the
class I/II HDAC inhibitor, TSA, resulted in E-cadherin
upregulation.16
We began our present studies with the goal of compar-
ing different HDAC inhibitors for their ability to upregulate
E-cadherin in NSCLC cells lines. MS-275, a class I HDAC
inhibitor,49 resulted in the largest induction and persistance of
E-cadherin compared with TSA, VPA, and VOR (Figure 1).
MS-275 inhibited the growth of NSCLC cell lines (Figure 2,
Table 1), similar to numerous reports with HDAC inhibitors
in other tumors. However, whether the upregulation of
E-cadherin plays any role in this process had not been investi-
gated to our knowledge. Importantly, we found that blocking
upregulation of E-cadherin by siRNA partially relieved the
growth suppression because of single-agent MS-275 (Figure
3). There are several possible mechanisms how this might
occur, which include among others effects on intercellular
adhesion, cell-cycle regulation, and associated changes in
growth factor signaling during epithelial-mesenchymal tran-
sition. Although more work will be required to elucidate the
responsible pathway(s), which may be context specific, we
conclude that E-cadherin has a distinct role in growth inhi-
bition mediated by HDAC inhibitors and that strategies to
upregulate E-cadherin might be additive or synergistic with
other biologic-based therapies to block tumor growth.
E-cadherin was induced by MS-275 in H2122, H460,
and H661 cells, and by VPA, TSA, and VOR in the latter two
lines, whereas none of these agents were effective in H157,
H1299, or H1703 (Figure 4A). Mechanistically, these results
suggest that HDACs recruited by transcriptional repressors
such as ZEB-1/2 are responsible for E-cadherin suppression
in about one half of those NSCLCs negative for this epithelial
adhesion molecule.
Interestingly, individual knockdowns of ZEB-1 or
ZEB-2 in H157 cells resulted only in modest upregulation of
E-cadherin mRNA (Figure 4B, note log10 scale) without any
observable protein accumulation (Figure 4C, lanes 3–5). In
contrast, the simultaneous knockdown of ZEB-1 and ZEB-2
resulted in synergistic E-cadherin mRNA upregulation
(1000-fold) and marked protein expression (lane 6). These
results emphasize the importance of ZEB-1 and -2, even
when class I/II HDACs are not apparently involved and
suggest that the two ZEB orthologs are not merely function-
ally redundant. Such cooperativity might occur, for example,
if each factor recruited different components to the E-cad-
herin promoter, which together resulted in less accessibility
of the DNA than either factor alone. Alternatively, ZEB-1
and -2 may bind distinct E-cadherin regulatory sites. The lack
of response to class HDAC I/II inhibitors may also be due to
the involvement of a class III enzyme.50 However, we do not
know at present whether the inhibition is CtBP dependent or
might result from another suppressive mechanism.51 In H661
cells, we observed displacement of ZEB-1 from the SEMA3F
promoter on treatment with VOR.17 In H157 cells, our ob-
servation that E-cadherin silencing is ZEB dependent, but
class I/II HDAC independent implies that ZEB factor dis-
TABLE 3. Taxotere IC50 and Combination Index with MS-275
Cell Line Histology
IC50 (M)
a
Taxotere
IC50 (M)
a
MS-275 CI
	MS-275/Tax

at Peak Synergy
H647 Ad-sq 0.00419  .001 1.74  0.31 0.199 0.45/0.014
H322 Bac 0.0029  .00029 9.18  1.64 0.441 0.45/0.014
H290 Meso 0.065  0.019 0.79  0.13 0.197 0.4/0.05
H661 Large 0.0031  0.0001 0.43  0.12 0.395 1.35/0.014
H1793 Adeno 0.150 5.48  1.19 0.200 0.15/0.04
H513 Meso 0.022  0.014 2.00  0.6 0.129 0.3125/0.005
H292 Mucoepi 0.0024  0.0007 1.15  0.24 0.244 0.15/0.014
H157 Squamous 0.015  0.005 0.75  0.21 0.121 0.3125/0.005
H1648 Adeno 0.0019  0.0003 0.45  0.15 0.080 0.45/.014
A549 Adeno 0.022  0.014 3.42  0.92 0.216 0.3125/0.005
H460 Large 0.010  0.004 0.55  0.1 0.553 5.0/0.05
H2122 Adeno 0.025  0.012 0.26  0.06 0.265 0.15/0.005
a Values are means  SD for three experiments, each done in triplicate.
CI, combination index.
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FIGURE 6. MS-275 induces apoptosis in non-small cell lung cancer (NSCLC) cell lines. A–D, The indicated NSCLC cell lines
were incubated with medium (controls), MS-275 (10 M), or trichostatin A (TSA, 0.33 M), as indicated, for 48 hours. The
percentage of apoptotic cells was determined by flow cytometry using dual staining with YO-PRO1 and propidium iodide. A,
C, Flow analysis of untreated control cultures for H661 (A) and H290 (C ). B, D, Flow analysis of H661 cells after treatment
with TSA (B) and H290 cells after treatment with MS-275 (D). E, F, MS-275 activates caspase-3 in sensitive NSCLC cell lines. E,
F, The moderately sensitive line H647 and the resistant line A549 were treated with MS-275 at different doses (E ) or times (F )
and examined for biochemical changes indicative of apoptosis. In (E ), cultures were treated for 36 hours with the indicated
doses of MS-275 (M); in (F ), cultures were treated with 5 M MS-275 for the indicated times. Lysates were analyzed by
Western blot for activated caspase 3 and poly ADP ribose polymerase (PARP) cleavage. Tubulin provided loading controls. (G )
Bcl-2 protein levels were measured in 14 non-small cell lung cancer (NSCLC) lines, as indicated. Signals from a shorter expo-
sure (not shown) were densitized and normalized to the level obtained in A549 to yield relative expression (Rel Exp). A Coo-
massie stained gel (Coom.) provided a loading control.
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placement may be cell line specific and/or may depend on the
specific HDACs recruited.
Upregulation of E-cadherin in H157 cells had a potent
effect on in vivo tumorigenicity. As shown in Figure 5, two
clones of H157 cells stably expressing comparable amounts
of E-cadherin were markedly attenuated in their ability to
form tumors when injected orthotopically into the lungs of
nude rats. These results validate the tumor suppressing con-
tribution made by E-cadherin in NSCLC.
There are numerous preclinical and clinical reports
examining the effects of HDAC inhibitors alone and in
combination with other agents.22–28,52 HDAC inhibitors se-
lectively induce apoptosis in cancer cells through changes in
levels and activities of pro- and antiapoptotic proteins, stress
kinases, reactive oxygen species and, as recently described,
from inhibition of proteasome function.21,53–56 As expected,
single-agent MS-275 induced apoptosis in NSCLC cells, as
evidenced by Annexin V staining, PARP cleavage, and
caspase 3 activation (Figure 6A–F).
In limited experiments, we explored the combination of
MS-275 with either paclitaxel, a microtubule stabilizing agent,
or 17-AAG, an inhibitor of HSP90. With paclitaxel, synergistic
growth inhibition was observed (Table 3). Taxols inhibit micro-
tubule function and induce apoptosis in a caspase-dependent
manner.57 In addition, microtubule function is regulated in part
by acetylation, with the class II enzyme, HDAC6, being an
important microtubule deacetylase. However, MS-275 has no
in vitro activity against HDAC6,49 implying that there must
be a different mechanism of action to explain the synergy.
The combination of HDAC and HSP90 inhibitors has been
less well studied. In leukemia cells, the class I/II inhibitor,
VOR, enhanced the antitumor activity of 17-AAG reportedly
through its activity against HDAC6, which removes acetyl
groups from HSP90 enhancing its function.30 In addition,
HDAC6 was shown to be an HSP90 client protein. We
observed that MS-275 plus 17-AAG synergistically inhibited
growth in most NSCLC cell lines (Table 2). As with pacli-
taxel, the expected mechanism of synergy should be other
than HDAC6 inhibition, although we do not know whether it
is affected indirectly. One further observation is that neither
the presence of apoptosis nor BCL-2 levels significantly
correlated with the degree of growth inhibition (Table 1),
which would be consistent with a multifactorial explanation
for the antigrowth properties of these agents.
In conclusion, we found that MS-275 was the most
effective HDAC inhibitor to upregulate E-cadherin in these
NSCLC cell lines. Furthermore, E-cadherin upregulation
seems to play a role in HDAC inhibitor-mediated growth
inhibition and, when stably transfected, has a potent in vivo
antitumor effect. The results presented here also confirm our
previous findings concerning the predominant role played by
ZEB proteins in E-cadherin transcriptional repression in
NSCLC cell lines. Moreover, ZEB-1 and ZEB-2 can contrib-
ute in a synergistic manner to E-cadherin suppression, and, in
some cases, their effects are independent of class I/II HDACs,
a finding which has potential therapeutic importance. The
combination of MS-275 with either paclitaxel or HSP90
inhibitor seems promising.
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